09-25-2015, 11:22 PM
Daniel Carder, an unassuming 45-year-old engineer with gray hair and blue jeans, appears an unlikely type to take down one of the world's most powerful companies. But he and his small research team at West Virginia University may have done exactly that, with a $50,000 study which produced early evidence that Volkswagen AG was cheating on U.S. vehicle emissions tests, setting off a scandal that threatens the German automaker's leadership, reputation and finances.
Meet the man who uncovered Volkswagen's lie
Sharp has announced that it will begin selling its 8K televisions from this October. While this is exciting for the future of TV, it's a treat reserved for the rich. The 85-inch Sharp LV-85001 8K television will cost a hefty $133,000 which is about £86,000 to buy. It offers a resolution that’s 16 times that of 1080p.
Putting the Sharp in TV, 8K screens coming this October - Pocket-lint
Giant house spiders have invaded a Cheshire town as millions of Britain's largest creepy-crawlies look set to overrun homes across the country. Residents of Macclesfield have reported finding spiders as big as mice and fear they are looking for a spot to lay hundreds of eggs.
Invasion of giant house spiders after Britain's wet summer - Telegraph
Workers of the world are about to get their revenge. Owners of capital will have to make do with a shrinking slice of the cake. The powerful social forces that have flooded the global economy with abundant labour for the past four decades years are reversing suddenly, spelling the end of the deflationary super-cycle and the era of zero interest rates. "We are at a sharp inflexion point," says Charles Goodhart, a professor at the London School of Economics and a former top official at the Bank of England. As cheap labour dries up and savings fall, real interest rates will climb from sub-zero levels back to their historic norm of 2.75pc to 3pc, or even higher.
Deflation supercycle is over as world runs out of workers - Telegraph
"They take drugs that have largely been underpriced before—or that's the way they'd call it," Gal said in a telephone interview. "They buy a drug that does not have good alternatives and they raise the price sky-high. And because it's very hard to say no to those patients; because there's no alternative, people cover this." Gal pointed to three examples: Jazz Pharmaceuticals' drug Xyrem, Questcor's Acthar and Mylan's EpiPen.